Picture loading failed.

Pre-Made Obexelimab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Obexelimab (XmAb 5871) is an anti-CD19 monoclonal antibody that is being developed by Xencor for the treatment of autoimmune disorders including IgG4-related disease, systemic lupus erythematosus and rheumatoid arthritis. Xencor designed the antibody using its XmAb® technology.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-383-1mg 1mg 3090
GMP-Bios-ab-383-10mg 10mg Inquiry
GMP-Bios-ab-383-100mg 100mg Inquiry
GMP-Bios-ab-383-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Obexelimab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody
INN Name Obexelimab
TargetCD19
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesXencor
Conditions Approvedna
Conditions ActiveAutoimmune disorders;Rheumatoid arthritis;Systemic lupus erythematosus
Conditions Discontinuedna
Development TechXmAb Antibody Engineering Technology